phrykt

Regeneron Pharmaceuticals (REGN) net income: $4.5B

Regeneron Pharmaceuticals reported a net income of $4.5B for the year ended Dec 31, 2025, up 2.1% from $4.4B a year earlier.

From Regeneron Pharmaceuticals's filings with the SEC · Read the filing · REGN stock page

Regeneron Pharmaceuticals net income by year

$8.1B2021$4.3B2022$4B2023$4.4B2024$4.5B2025

#98 of 3,748 US companies by net income · See the full ranking

Year endedNet incomeChange
Dec 31, 2025$4.5B+2%
Dec 31, 2024$4.4B+12%
Dec 31, 2023$4B-9%
Dec 31, 2022$4.3B-46%
Dec 31, 2021$8.1B–

Net income of similar companies

Companies in the same industry as Regeneron Pharmaceuticals, by SEC industry code, with the closest net income. Each name opens the same page for that company.

CompanyNet income, latest yearYear ended
Pfizer$7.8BDec 31, 2025
Bristol Myers Squibb$7.1BDec 31, 2025
Abbott Laboratories$6.5BDec 31, 2025
Regeneron Pharmaceuticals$4.5BDec 31, 2025
AbbVie$4.2BDec 31, 2025
Vertex Pharmaceuticals Inc / Ma$4BDec 31, 2025
Zoetis$2.7BDec 31, 2025

Questions and answers

What is Regeneron Pharmaceuticals's net income?

Regeneron Pharmaceuticals reported a net income of $4.5B for the year ended Dec 31, 2025, up 2.1% from $4.4B a year earlier.

Numbers as reported in Regeneron Pharmaceuticals's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology